Spoken Alpha
Outlook Therapeutics, Inc.
Outlook Therapeutics develops ONS-5010/LYTENAVA, an ophthalmic formulation of bevacizumab approved in the EU and UK for treating wet age-related macular degeneration.
Outlook Therapeutics, Inc is a Healthcare company operating in Biotechnology with a $158.9M market cap.
OTLK beat consensus EPS by 0.0% in Q3 FY2026, reported Aug 13, 2026.
3 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from SEC 10-K filing, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for OTLK.
$ curl https://api.spokenalpha.com/v1/companies/OTLKFAQ
Spoken Alpha indexes OTLK's earnings call transcripts at https://spokenalpha.com/companies/OTLK. Each call links to attributed speakers and parsed analyst Q&A. Outlook Therapeutics, Inc.'s own investor relations page is at https://ir.outlooktherapeutics.com/.
Outlook Therapeutics, Inc. (OTLK) held its most recent earnings call on 2026-08-14, covering fiscal Q3 2026.
Outlook Therapeutics, Inc. (OTLK) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-08-13 | $-0.09 | $-0.09 | 0.0% | $9.0K | — | — | EODHD |
| Q2 FY2026 | 2026-05-14 | $-0.17 | $-0.12 | -41.7% | $127.4K | — | — | EODHD |
| Q1 FY2026 | 2026-02-16 | $-0.22 | $-0.17 | -29.4% | $-1.2M | — | — | EODHD |
| Q4 FY2025 | 2025-12-18 | $-0.28 | $-0.06 | -100.0% | $-91.8K | — | — | EODHD |
| Q3 FY2025 | 2025-08-13 | $-0.44 | $-0.39 | -12.8% | $1.5M | — | — | EODHD |
| Q2 FY2025 | 2025-05-14 | $-0.40 | $-0.55 | +27.3% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-02-13 | $0.72 | $-0.62 | +100.0% | $170.1K | — | — | EODHD |
| Q4 FY2024 | 2024-12-19 | $-0.94 | $-0.90 | -4.1% | $170.1K | — | — | EODHD |
| Q3 FY2024 | 2024-08-13 | $-0.83 | $-0.84 | +1.2% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-05-14 | $-1.55 | $-1.07 | -44.9% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-02-13 | $-0.78 | $-1.07 | +27.1% | $0 | — | — | EODHD |
| Q4 FY2023 | 2023-12-21 | $-0.05 | $-0.06 | +16.7% | $0 | — | — | EODHD |
| Q3 FY2023 | 2023-08-13 | $-1.38 | $-0.87 | -58.6% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-05-14 | $-0.52 | $-1.20 | +56.7% | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-02-13 | $-1.59 | $-1.30 | -22.3% | $0 | — | — | EODHD |
| Q4 FY2022 | 2022-12-28 | $-0.06 | $-0.07 | +14.3% | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-08-09 | $-1.56 | $-1.33 | -17.3% | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-05-12 | $-1.77 | $-1.20 | -47.5% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-02-13 | $-0.08 | $-0.06 | -33.3% | $0 | — | — | EODHD |
| Q4 FY2021 | 2021-12-21 | $-1.60 | $-1.27 | -26.0% | $0 | — | — | EODHD |
Source: EODHD. OTLK reported actuals as published; sparse fields render as —.